natgillin/translations-raw huggingface dataset:
Poročali so o občasnih primerih radiacijske pljučnice pri bolnikih, ki so jih zdravili z radiacijo pred, med ali po njihovem zdravljenju s pemetreksedom (glejte poglavje 4.4).
Uncommon cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy (see section 4.4).
Poročali so o pojavu nevtropeničnega kolitisa, vključno z usodnim nevtropeničnim kolitisom, kot zapletu s topotekanom povzročene nevtropenije (glejte poglavje 4.4).
1Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section 4.4).
Poročali so o poslabšanju delovanja ledvic, napredovanju v ledvično odpoved in dializi po začetnem odmerku ali po enkratnem odmerku 4 mg zoledronske kisline.
Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid.
Poročali so o povprečno manjši toksičnosti ter znižanju hematoloških in nehematoloških toksičnosti stopnje 3/4, denimo nevtropeniji, febrilni nevtropeniji ter okužbi z nevtropenijo stopnje 3/4, kadar so pred zdravljenjem dajali folno kislino in vitamin B12.
Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities, such as neutropenia, febrile neutropenia, and infection with Grade 3/4 neutropenia, were reported when pre- treatment with folic acid and vitamin B12 was administered.
Poročali so o prevelikem odmerjanju pri bolnikih, ki so bili zdravljeni z intravenskim topotekanom (do 10-kratni priporočeni odmerek) in topotekan kapsulami (do 5-kratni priporočeni odmerek).
Overdoses have been reported in patients being treated with intravenous topotecan (up to 10 fold of the recommended dose) and topotecan capsules (up to 5 fold of the recommended dose).
Poročali so o primerih radiacijske pljučnice pri bolnikih, ki so jih zdravili z radiacijo pred, med ali po zdravljenju s pemetreksedom.
Cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during, or subsequent to their pemetrexed therapy.
Poročali so o radiacijskem izpuščaju pri bolnikih, ki so se zdravili z radioterapijo pred tedni ali leti.
Cases of radiation recall have been reported in patients who received radiotherapy weeks or years previously.
Poročali so o razvoju aritmij in nevroloških neželenih dogodkov (vključno s konvulzijami, hipestezijo in tetanijo), do katerih je prišlo zaradi hude hipokalciemije.
Cardiac arrhythmias and neurologic adverse events (including convulsions, hypoaesthesia and tetany) have been reported secondary to cases of severe hypocalcaemia.
Poročali so o redkih primerih anafilaktičnega šoka.
Rare cases of anaphylactic shock have been reported.
Poročali so o redkih primerih buloznih stanj, kot sta Stevens-Johnsonov sindrom in toksična epidermalna nekroliza, ki so bila v nekaterih primerih usodna.
Rare cases of bullous conditions have been reported including Stevens-Johnson syndrome and Toxic epidermal necrolysis which in some cases were fatal.
Poročali so o redkih primerih radiacijskega izpuščaja pri bolnikih, ki so se v preteklosti zdravili z radioterapijo (glejte poglavje 4.4).
Rare cases of radiation recall have been reported in patients who have received radiotherapy previously (see section 4.4).
Poročali so o resnih ledvičnih primerih, vključno z akutno ledvično odpovedjo, s pemetreksedom samim ali v povezavi z drugimi kemoterapevtiki.
Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents.
Poročali so tudi o bolečinah v okončinah, nizki temperaturi in bledosti okončin.
Extremity pain, low temperature and discolouration have been reported.
Poročali so tudi o motnjah srčnega ritma (aritmiji), napadih krčev, posameznih krčih in trzanju (tetaniji), do katerih pride zaradi hude hipokalciemije.
Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia.
Poročali so tudi o primerih hude hipokalciemije, zaradi katere je bilo treba bolnika hospitalizirati.
Cases of severe hypocalcaemia requiring hospitalisation have been reported.
Poročali so, da lahko pemetreksed povzroči utrujenost.
It has been reported that pemetrexed may cause fatigue.
Poročani neželeni učinki v študiji so bili podobni neželenim učinkom, poročanim v študijah psoriaze s plaki pri odraslih.
In this study, the adverse events reported were similar to those seen in previous studies in adults with plaque psoriasis.
Poročanje o domnevnih neželenih učinkih zdravila po izdaji dovoljenja za promet je pomembno.
Reporting of suspected adverse reactions after authorisation of the medicinal product is important.
Poročila o resnih zapletih, povezanih s trombocitopenijo, vključno s smrtnimi primeri in krvavitvami tumorjev, so bila redka.
Reports of significant sequelae associated with thrombocytopenia including fatalities due to tumour bleeds have been infrequent.
Poročila v literaturi kažejo, da je mogoča posledica zdravljenja drugih indikacij z dopaminergičnimi zdravili poslabšanje simptomov.
Reports in the literature indicate that treatment of another indication with dopaminergic medicinal products can result in augmentation.
Porriño Pontevedra 36400 Испания
Porriño Pontevedra 36400 Spain
Portfarma ehf.
Pharmathen S.A.
Portrazza + GCб (N=538)
Portrazza + GCb (N=538)
Portrazza 800 mg концентрат да инфузионен разтвор нецитумумаб (necitumumab)
Portrazza 800 mg concentrate for solution for infusion necitumumab
Portrazza 800 mg концентрат за инфузионен разтвор
Portrazza 800 mg concentrate for solution for infusion
Portrazza 800 mg концентрат за инфузионен разтвор (стерилен концентрат) е прозрачна до слабо опалесцираща или безцветна до бледожълта течност в стъклен флакон с гумена запушалка.
Portrazza 800 mg concentrate for solution for infusion (sterile concentrate) is a clear to slightly opalescent and colourless to slightly yellow liquid in a glass vial with a rubber stopper.
Portrazza 800 mg стерилен концентрат нецитумумаб
Portrazza 800 mg sterile concentrate necitumumab
Portrazza е лекарство за лечение на напреднали стадии на вид белодробен рак, известен като сквамозен недребноклетъчен рак на белия дроб.
Portrazza is a medicine for treating advanced stages of a type of lung cancer known as squamous non- small cell lung cancer.
Portrazza може да причини образуване на съсиреци във Вашите артерии или вени.
Portrazza can cause blood clots in your arteries or your veins.
Portsmouth, NH 03801-2815 САЩ
Portsmouth, NH 03801-2815 United States
Portugal
España
Portugal
France
Portugal
France Portugal
Portugal
Hrvatska
Portugal
Lietuva
Portugal
Nederland
Portugal
Polska
Portugal
România
Portugal
Slovenija
Portugal
Suomi/Finland
Portugal medac GmbH - Sucursal em Portugal Tel: +351 21 410 75 83
Portugal medac GmbH - Sucursal em Portugal Tel: + 351 21 410 75 83
Portugal MediWound GmbH Tel: +800 22232425
Tel: +800 22232425
Portugal ratiopharm, Comércio e Indústria de Produtos farmacêuticos Lda
ratiopharm, Comércio e Indústria de Produtos farmacêuticos Lda
Portugalska
Portugal
Porucha funkce jater
Hepatic impairment
Porucha funkce ledvin
Renal impairment
Porucha funkce ledvin Atazanavir
Renal impairment Atazanavir
Porucha funkcie obličiek
Renal impairment
Porucha funkcie pečene
Hepatic impairment
poruchy chůze
gait disturbance
poruchy chůze (abnormální způsob chůze)
gait disturbance (abnormal manner of walking)
Poruchy ciev
Vascular Disorders
Poruchy dýchacej sústavy, hrudníka a mediastína
Respiratory, Thoracic and Mediastinal Disorders
Poruchy funkce jater Atazanavir
Hepatic impairment Atazanavir
Poruchy funkce ledvin
Renal impairment
Poruchy funkcie obličiek
Renal impairment
Poruchy funkcie pečene
Hepatic impairment
Poruchy gastrointestinálneho traktu
Gastrointestinal disorders
Poruchy imunitního systému
Immune system disorders
Poruchy jater a žlučových cest
Hepato-biliary disorders
Poruchy jater a žlučových cest
Hepatobiliary disorders
Poruchy jater a žlučových cest
pancreatitis, gastritis, stomatitis aphthous
Poruchy kože a podkožného tkaniva
Skin and subcutaneous tissue disorders
Poruchy krve a lymfatického systému
Blood and lymphatic system disorders
Poruchy krvi a lymfatického systému
Blood and lymphatic system disorders
Poruchy ledvin a močových cest
Gastrointestinal disorders
Poruchy ledvin a močových cest
Renal and urinary disorders
Poruchy lipidů je třeba léčit podle klinické potřeby.
Lipid disorders should be managed as clinically appropriate.
Poruchy metabolismu a výživy
Metabolism and nutrition disorders
Poruchy metabolizmu a výživy
increased appetite
Poruchy metabolizmu a výživy
Metabolism and Nutrition Disorders
Poruchy nervového systému
Nervous System Disorders
Poruchy oka
Eye disorders
Poruchy pečene a žlčových ciest
Hepatobiliary disorders
Poruchy svalové a kosterní soustavy a pojivové tkáně
Musculoskeletal, connective tissue and bone disorders
Poruchy ucha a labyrintu
Ear and labyrinth disorders
Posaconazole SP 40 mg/ml перорална суспензия
Posaconazole SP 40 mg/ml oral suspension
Posaconazole SP 40 mg/ml перорална суспензия позаконазол
Posaconazole SP 40 mg/ml oral suspension posaconazole
Posaconazole SP може да се използва за лечение на следните гъбични инфекции при възрастни:
Posaconazole SP can be used to treat the following types of fungal infections in adults:
Posaconazole SP не трябва да се приема с лекарства, които са субстрати на CYP3A4 и за които се знае, че удължават QTc интервала (вж. точки 4.3 и 4.5).
Posaconazole SP must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5).
Posaconazole SP трябва да се приема точно както Ви е казал Вашият лекар.
Posaconazole SP must only be used as directed by your doctor.
Posaconazole е от 40 до 100 пъти по-ефикасен в in vitro тестове срещу Malassezia pachydermatis в сравнение с clotrimazole, miconazole и nystatin.
Posaconazole is 40 – 100 times more potent in vitro against Malassezia pachydermatis than clotrimazole, miconazole and nystatin.
Posatex капки за уши суспензия за кучета
Posatex ear drops for dogs
Posatex капки за уши суспензия за кучета
Posatex ear drops suspension for dogs
Posatex капки за уши суспензия за кучета.
Posatex, ear drops suspension for dogs
Posatex капки за уши, суспензия за кучета
Posatex ear drops suspension dogs
Posatex капки за уши, суспензия за кучета
Posatex ear drops suspension for dogs
Posatex капки за уши, суспензия за кучета.
Posatex ear drops suspension for dogs
Posebej morate biti pozorni na pritrjevanje regulatorja tlaka, da bi preprečili morebitne okvare.
A particular attention should be also turned to the fastening of the pressure regulator so as to avoid the risks of accidental failures.
Posebej pazljivi morate biti, če jemljete: druga zdravila na osnovi fluoropirimidinov, kot je antimikotik flucitozin.
You need to be particularly careful if you are taking any of the following: other fluoropyrimidine based medicines such as the anti-fungal flucytosine.
Posebna navodila za shranjevanje
Special precautions for storage
Posebna navodila za shranjevanje
Special precautions for storage‌‌‌
POSEBNA NAVODILA ZA SHRANJEVANJE
SPECIAL STORAGE CONDITIONS
POSEBNA NAVODILA ZA SHRANJEVANJE
SPECIAL STORAGE PRECAUTIONS
Posebna opozorila in previdnostni ukrepi
Special warnings and precautions for use
Posebna opozorila za uporabo pri živalih:
Special precautions for use in animals: Vaccinate only healthy rabbits.
Posebna opozorila za vsako ciljno živalsko vrsto
Special warnings for each target species
POSEBNA OPOZORILA, ČE SO POTREBNA
SPECIAL WARNING(S), IF NECESSARY
Posebne populacije
Special populations
Posebne skupine
Special populations
Posebne skupine bolnikov
Special patient populations
Posebni previdnostni ukrepi
Special precautions for use
Posebni previdnostni ukrepi za uporabo pri živalih
Special precautions for use Special precautions for use in animals
Posebni varnostni ukrepi za odstranjevanje
Special precautions for disposal
Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
6.6 Special precautions for disposal and other handling
Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Special precautions for disposal
Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Special precautions for disposal and other handling
Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom‌‌‌‌
Special precautions for disposal and other handling
Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi
Special precautions for the disposal of unused medicinal product or waste materials, if any
Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Posebni varnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo
Special precautions to be taken by the person administering the product
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
Posebno skrbno je treba paziti na natančno odmerjanje zdravila.
Particular care should be taken with regard to the accuracy of dosing.
POSEBNO(A) OPOZORILO(A)
SPECIAL WARNING(S)
POSEBNO(A) OPOZORILO(A), ČE JE (SO) POTREBNO(A)
SPECIAL WARNING(S), IF NECESSARY
POSEBNO(A) OPOZORILO(A), ČE JE(SO) POTREBNO(A)
SPECIAL WARNING(S), IF NECESSARY
Positivt
Coombs
Positivt Coombs direkttest (se avsnitt 4.4)
Direct Test Positive (see  section 4.4)
Poskusi na živalih so pokazali, da dušikov oksid lahko vpliva na hemostazo in podaljša krvavitve.
Animal models have shown that nitric oxide may interact with haemostasis, resulting in an increased bleeding time.
Poskusi na živalih so pokazali, da pramipeksol zavira sintezo, sproščanje in hitrost obračanja ('turnover') dopamina.
Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover.
Poslabšanje delovanja ledvic, napredovanje v ledvično odpoved in dializo so bili zabeleženi pri bolnikih po začetnem ali enkratnem odmerku 4 mg zoledronske kisline (glejte poglavje 4.4).
Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid (see section 4.4).
Poslabšanje oksigenacije in povišanje PAP se lahko pojavita tudi pri novorojenčkih, pri katerih ni očitnega odziva na zdravilo INOmax.
Deterioration in oxygenation and elevation in PAP may also occur in neonates with no apparent response to INOmax.
Poslabšanje simptomov
Augmentation
Poslabšanje simptomov so raziskovali v nadzorovanem kliničnem preskušanju, ki je trajalo 26 tednov.
Augmentation was specifically investigated in a controlled clinical trial over 26 weeks.
poslabšanje sladkorne bolezni, debelost
Diabetes mellitus aggravated, Obesity
Posledično obstaja veliko tveganje za razvojno toksičnost pri kliničnih odmerkih, predvsem zaradi tegafurja (5-FU), v manjši meri pa zaradi oteracila.
There is therefore a high risk for developmental toxicity at clinical doses, primarily due to tegafur (5-FU) and to oteracil to a lesser extent.
Possia (%/година) N=9235
Possia (%/year) N=9235
Possia 90 mg таблетки ticagrelor
Possia 90 mg tablets ticagrelor
Possia 90 mg филмирани таблетки тикагрелор (ticagrelor)
Possia 90 mg film-coated tablets ticagrelor
Possia e малко вероятно да повлияе способността Ви да шофирате или да работите с машини.
Possia is not likely to affect your ability to drive or use machines.
Possia действа на клетки, наречени „тромбоцити” (още наречени „кръвни плочици”).
Possia affects cells called ‘platelets’ (also called thrombocytes).
Possia не повлиява белодробните функционални тестове.
Possia does not affect tests of pulmonary function.
Possia не се препоръчва за деца и юноши под 18 години.
Possia is not recommended for children and adolescents under 18 years.
Possia не се препоръчва по време на бременност.
Possia is not recommended during pregnancy.
Possia обаче не е по-ефективен от клопидогрел за намаляване на риска от мозъчен удар.
However Possia was not more effective than clopidogrel in reducing the risk of stroke.
Possia се предлага в:
Possia is available in:
Possia тикагрелор
Possia ticagrelor
Post hoc анализ на времето до персистиращо 10% влошаване при 6MWD показва, че 26% от пациентите в групата с аталурен 10-, 10-, 20 mg/kg имат прогресия в седмица 48 в сравнение с 44% в групата с плацебо (p=0,0652) (Фигура 2).
A post-hoc analysis of time to persistent 10% worsening in 6MWD showed that 26% of patients in the ataluren 10-, 10-, 20-mg/kg arm had progressed at Week 48 compared to 44% in the placebo group (p=0.0652) (Figure 2).
Post hoc нестратифицирани подгрупови анализи на пациентите в проучването RAINBOW, които преди това са лекувани с трастузумаб (n= 39), предполагат полза за преживяемостта при такива пациенти (HR 0,679, 95% CI 0,327, 1,419) и показват полза за преживяемост без прогресия (PFS) (HR 0,399, 95% CI 0,194, 0,822).
Post hoc unstratified subgroup analyses from RAINBOW patients previously treated with trastuzumab (n= 39) suggested a survival benefit in such patients (HR 0.679, 95% CI 0.327, 1.419) and demonstrated a benefit for progression free survival (PFS) (HR 0.399, 95% CI 0.194, 0.822).
Post-hoc анализ на ефикасността при пациенти, които поддържат високо или много високо DRL при рандомизация
Post-hoc efficacy analysis in patients who maintained a high or very high DRL at randomisation
Post-hoc анализ на сериозни големи сърдечносъдови нежелани събития (сърдечносъдова смърт, инфаркт на миокарда, инсулт) от всички междинни и дългосрочни фаза 2 и 3 изпитвания (с продължителност от 26 до 100 седмици), включващи 5 607 пациенти (3 651 с експозиция на лираглутид) показва липса на повишение на сърдечносъдовия риск (коефициент на заболеваемост от 0,75 (95% CI 0,35; 1,63) за съставна крайна точка за лираглутид в сравнение с всички компаратори (метформин, глимепирид, розиглитазон, инсулин гларжин, плацебо)).
Post­hoc analysis of serious major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke) from all intermediate and long­term phase 2 and 3 trials (ranging from 26 and up to 100 weeks duration) including 5,607 patients (3,651 exposed to liraglutide), showed no increase in cardiovascular risk (incidence ratio of 0.75 (95% CI 0.35; 1.63) for the composite endpoint for liraglutide versus all comparators (metformin, glimepiride, rosiglitazone, insulin glargine, placebo)).
Post-hoc експлораторен
p=0.0011
Post-hoc експлораторен
Post-hoc exploratory analysis
Postfach 1108, 12474 Berlin
Postfach 1108, 12474 Berlin Tel.: 030/6707-0
Postopek
Procedure
POSTOPEK IN POT UPORABE ZDRAVILA
METHOD AND ROUTE(S) OF ADMINISTRATION
POSTOPEK IN POT(I) UPORABE ZDRAVILA
METHOD AND ROUTE(S) OF ADMINISTRATION
POSTOPEK IN POT(I) UPORABE ZDRAVILA
METHOD AND ROUTE(S) OF ADMINISTRATION:
Postopek preverjanja pred uporabo (niz korakov, potrebnih tik pred začetkom uporabe pri vsakem bolniku, da se prepričate, ali sistem deluje pravilno in je očiščen NO2)
Pre-use check list procedure (a series of steps required immediately prior to each patient initiation to ensure that the system is working properly and that the system is purged of NO2)
POSTOPEK UPORABE
METHOD OF ADMINISTRATION
Postoperativ smärta: enstaka intravenös eller subkutan injektion.
Post-operative pain: single intravenous or subcutaneous injection.
Postopki pravilne menjave jeklenk in čiščenja sistema
Procedures for correctly switching gas cylinders and purging system
Posvetujete se z zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se tudi, če opazite katere koli neželene učinike, ki niso navedeni v tem navodilu.
This includes any possible any side effects not listed in this leaflet.
Posvetujte se tudi, če opazite katere koli neželene učinke, ki niso navedni v tem navodilu.
If you have any side effects, including any side effects not listed in this leaflet, talk your doctor or pharmacist.
Posvetujte se tudi, če opazite neželene učinke, ki niso navedeni v tem navodilu.
This includes any possible side effects not listed in this leaflet.
Posvetujte se z zdravnikom ali farmacevtom, preden vzamete katero koli zdravilo.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se z zdravnikom ali farmacevtom, preden vzamete katerokoli zdravilo.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se z zdravnikom ali farmacevtom.
Please contact your doctor or pharmacist
Posvetujte se z zdravnikom ali s farmacevtom, preden boste vzeli katerokoli zdravilo.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se z zdravnikom ali s farmacevtom, preden vzamete katero koli zdravilo.
Ask your doctor or pharmacist for advice before taking any medicine.
Pot uporabe
Route of
Pot uporabe
Route of Administration
pot uporabe ovojnina
Route of
Pot uporabe zdravila
Route of Administration
POT(I) UPORABE ZDRAVILA
ROUTE(S) OF ADMINISTRATION
Potactasol 1 mg прах за концентрат за инфузионен разтвор
Potactasol 1 mg powder for concentrate for solution for infusion
Potactasol 1 mg прах за концентрат за инфузионен разтвор Potactasol 4 mg прах за концентрат за инфузионен разтвор топотекан (topotecan)
Potactasol 1 mg powder for concentrate for solution for infusion Potactasol 4 mg powder for concentrate for solution for infusion topotecan
Potactasol 1 mg прах за концентрат за инфузионен разтвор топотекан
Potactasol 1 mg powder for concentrate for solution for infusion topotecan
Potactasol 1 mg с 1,1 ml вода за инжекции (тъй като съдържа 10 % излишък при пълнене)
Potactasol 1 mg with 1.1 ml water for injections (as it contains 10 % overage of fill)
Potactasol 4 mg прах за концентрат за инфузионен разтвор
Potactasol 4 mg powder for concentrate for solution for infusion
Potactasol 4 mg прах за концентрат за инфузионен разтвор топотекан
Potactasol 4 mg powder for concentrate for solution for infusion topotecan
Potactasol 4 mg с 4 ml вода за инжекции
Potactasol 4 mg with 4 ml water for injections
Potactasol е „генерично лекарство“.
Potactasol is a ‘generic medicine’.
Potactasol може да намали Вашата способност да се борите с инфекциите.
Potactasol may reduce your ability to fight infections.
Potactasol може да причини намаляване на броя на клетките, отговорни за кръвосъсирването (тромбоцитите).
Potactasol may cause a decrease in the number of blood clotting cells (platelets).
Potactasol не се препоръчва в случай на сериозно бъбречно увреждане; ако имате проблеми с черния дроб.
Potactasol is not recommended in case of severe kidney impairment; if you have liver problems.